Search clinical trials for: Gardasil

Total 200 results

Medstar Health Research Institute
Merck Sharp & Dohme LLC

Completed

Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls?

Cervical Cancer | Warts | Hpv

United States
University Hospitals Cleveland Medical Center
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of Gardasil in Females With Juvenile Idiopathic Arthritis (JIA)/Seronegative Arthritis (CHASE)

Arthritis

United States
Oslo University Hospital
University Hospital, Akershus

Completed

Impact of HPV Vaccine On The Prevalence Of HPV In Norway

Cervical Cancer | Cervical Intraepithelial Neoplasia | Oropharyngeal Cancer

Norway
Universitaire Ziekenhuizen KU Leuven

Completed

Study of Safety, Tolerability and Immunogenicity of Gardasil®9 in Immunocompromised Patients

Hiv | Human Papilloma Virus | Organ Transplants

Belgium
Public Health England

Completed

Reactogenicity Study of Cervarix and Gardasil in UK Adolescent Girls (HPV CSP01)

HPV Infections

United Kingdom
Instituto Nacional de Salud Publica, Mexico

Completed

FASTER-Tlalpan Study in Mexico: HPV Vaccination Impact on Cervical Cancer Screening Program (FASTER)

Cervical Intraepithelial Neoplasia | HPV-Related Cervical Carcinoma

Mexico
GlaxoSmithKline

Completed

Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females

Infections, Papillomavirus | Papillomavirus Vaccines

Thailand, Estonia, India, Brazil
University of Witwatersrand, South Africa
Merck Sharp & Dohme LLC

Completed

Randomized, Double Blind Trial of the Quadrivalent HPV Vaccine to Improve Responses to LEEP Treatment of Cervical HSIL

Cervical High Grade Squamous Intraepithelial Lesion
Laval University

Completed

Immunogenicity of Gardasil and Twinrix and the Effect of a Dose of Gardasil or Cervarix Given 42 Months Later.

Human Papillomavirus

Canada
Merck Sharp & Dohme LLC

Completed

Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)

Uterine Cervical Neoplasms | Papillomavirus Infections | Vulvar Neoplasms | Vaginal Neoplasms | Condylomata Acuminata | Adenocarcinoma in Situ

Vietnam
GlaxoSmithKline

Completed

Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age

Infections, Papillomavirus | Papillomavirus Vaccines

United States
Merck Sharp & Dohme LLC

Completed

Safety and Tolerability Study of V501 in Japanese Boys (V501-200)

Condyloma Acuminata | Anogenital Human Papilloma Virus Infection

Japan
Merck Sharp & Dohme LLC

Completed

Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)

Cervical Cancer | Vulvar Cancer | Vaginal Cancer | Human Papillomavirus Infection | Genital Warts

Austria, Belgium, Finland, Germany, Italy, Spain
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females

Infections, Papillomavirus

Singapore, Hong Kong, France, Sweden
Buhai Wang
Innovent Biologics (Suzhou) Co. Ltd.

Unknown

Combination of PD-1 Monoclonal Antibody and HPV Vaccine in Patients With Cervical Cancer

Cervical Cancer | Uterine Cervical Neoplasms | Cervix Cancer | Cervical Neoplasms

China
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Gardasil Vaccination in Post Stem Cell Transplant Patients

Stem Cell Transplant | Immunogenicity | Gardasil Vaccine

United States
University of Fukui
Merck Sharp & Dohme LLC

Unknown

The Prospective Cohort Study to Evaluate the Preventive Efficacy of HPV Vaccine in Japanese Women Aged 27-45 Years

Vaccinia | Cancer of Cervix
Kenya Medical Research Institute
Merck Sharp & Dohme LLC; University of Washington

Completed

A Cohort Study to Assess Sustained Immunogenicity to qHPV Vaccine Among HIV-infected Girls and Boys Age 9-14 Years

HIV-1 Infection | Human Papillomavirus
Odense University Hospital

Completed

Adherence in Topical Treatment of Psoriasis

Adherence

Denmark
CHU de Reims

Completed

Comparing Health Services Interventions for the Prevention of HPV-related Cancer (CoheaHr-WP4)

Cervical Cancer

France
Merck Sharp & Dohme LLC

Completed

Efficacy and Tolerability Study of V501 in Japanese Males (V501-122)

Condyloma Acuminata | Anogenital Human Papilloma Virus Infection
Merck Sharp & Dohme LLC

Completed

Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041)

HPV Infections
Laval University

Completed

Immunogenicity and Safety of Gardasil-9 and Cervarix

HPV Vaccines Immunogenicity and Safety

Canada
Cumberland Pharmaceuticals

Completed

Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI) (FAST2)

Infections, Gram-positive Bacterial

United States
Pfizer

Completed

A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17

Vaccines | Meningococcal Vaccines

United States
Merck Sharp & Dohme LLC

Completed

Immunogenicity and Tolerability of V503 Versus GARDASIL (V503-009)

Human Papillomavirus
Merck Sharp & Dohme LLC

Completed

V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110)

Cervical Cancer | Cervical Intraepithelial Neoplasia | Adenocarcinoma in Situ
Merck Sharp & Dohme LLC

Completed

Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)

Cervical Cancer | Vulvar Cancer | Vaginal Cancer | Human Papillomavirus Infection | Genital Warts
Merck Sharp & Dohme LLC

Completed

A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)

Genital Warts | Cervical Cancers | Vulvar Cancers | Vaginal Cancers
Merck Sharp & Dohme LLC

Completed

GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)

Papillomavirus Infections
Wayne State University
Merck Sharp & Dohme LLC

Completed

Study to Determine if Gardasil Vaccine is Safe and Effective in Lupus Patients (GARDASIL)

Systemic Lupus Erythematosus

United States
Merck Sharp & Dohme LLC

Completed

A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men (V503-020)

Papilloma Viral Infection

Belgium, Germany, Netherlands
Beijing Chaoyang District Centre for Disease Control...

Unknown

Post-Approval Safety Monitoring Program to Assess the Safety Profile of GARDASIL in China Usual Practice

Cervical Cancer
Instituto Nacional de Salud Publica, Mexico
Secretaria de Salud, Mexico

Completed

Evaluation of Immunogenicity Levels in Women With HPV Vaccine in Mexico

Healthy

Mexico
Merck Sharp & Dohme LLC

Completed

An Investigational Study of Gardasil™ (qHPV Vaccine) in Reducing the Incidence of Anogenital Warts in Young Men (V501-020)

Condylomata Acuminata
Planned Parenthood Federation of America
Merck Sharp & Dohme LLC

Completed

Innovative Tool to Increase Completion of Human Papillomavirus (HPV) Vaccine Series

GARDASIL Vaccination

United States
Sarah Hostetter, MD

Completed

Gardasil Knowledge

HPV

United States
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; University of Michigan

Completed

Community Awareness, Resources and Education (CARE II): Project 3

Uterine Cervical Cancer

United States
University of North Carolina, Chapel Hill
Merck Sharp & Dohme LLC

Completed

Adolescent Vaccination in Pharmacies (AVIP)

Evaluating Attitudes Toward HPV Vaccinations in Pharmacies | Evaluating the Provision of HPV Vaccines in a Pharmacy

United States
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology

Terminated

Captopril in Treating Patients With Non-Small Cell Lung Cancer or Limited-Stage Small Cell Lung Cancer That Has Been Previously Treated With Radiation Therapy With or Without Chemotherapy

Lung Cancer | Pulmonary Complications | Radiation Fibrosis

United States
St. Louis University

Withdrawn

Gardasil Administration

Vaccine Administration Rates

United States
Assistance Publique - Hôpitaux de Paris

Unknown

Efficacy of Quadrivalent HPV Vaccine to Prevent Relapses of Genital Warts After Initial Therapeutic Response (CONDYVAC)

Genital Warts

France
Merck Sharp & Dohme LLC

Completed

A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018)

Papillomavirus Infections | Human
University of Chicago
Merck Sharp & Dohme LLC

Completed

Immunogenicity and Safety of HPV Vaccine Gardasil in Young Women

Systemic Lupus Erythematosus

United States
Laval University
Centers for Disease Control and Prevention

Completed

Immunogenicity of One Dose of Gardasil and One Dose of Gardasil-9

Human Papillomavirus Vaccines

Canada
Johns Hopkins University
Merck Sharp & Dohme LLC

Completed

Antibody Response to Human Papillomavirus Recombinant Vaccine (Gardasil®) in Girls and Young Women With Chronic Kidney Disease

Chronic Kidney Disease

United States
Merck Sharp & Dohme LLC
Kaiser Permanente

Completed

Observational Surveillance Study to Detect Potential Safety Signals in Patients Who Have Had at Least One Dose of GARDASIL™ (V501-031)

Human Papillomavirus Infection
University of Louisville
Merck Sharp & Dohme LLC

Completed

Health Care Decisions for Female Adolescents: The Role of Mothers and Daughters in Decision Making

Cervical Cancer

United States
Merck Sharp & Dohme LLC

Completed

V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)

HPV Infections
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019)

Prevention | Papillomavirus Infection | Healthy Adult Female Participants | Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18

Search clinical trials for: Gardasil

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Thailand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations